Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial

Carolyn T. Bramante, Kenneth B. Beckman, Tanvi Mehta, Amy B. Karger, David J. Odde, Christopher J. Tignanelli, John B. Buse, Darrell M. Johnson, Ray Watson, Jerry J Daniel, David Liebovitz, Jacinda M. Nicklas, Ken Cohen, Michael A. Puskarich, Hrishikesh Belani, Lianne Siegel, Nichole R. Klatt, Blake Anderson, Katrina M Hartman, Via Rao, Aubrey A Hagen, Barkha Patel, Sarah L. Fenno, Nandini Avula, Neha V Reddy, Spencer M Erickson, Regina Fricton, Samuel Lee, Gwendolyn Griffiths, Matthew F Pullen, J. L. Thompson, Nancy E. Sherwood, Thomas A. Murray, Michael R. Rose, David R. Boulware, Jared D. Huling, the Covid-out study teammedRxiv 2023 · DOI

TL;DR

Metformin, a widely used and inexpensive diabetes medication, significantly reduces SARS-CoV-2 viral load by approximately 3.6-fold compared to a placebo. This Phase 3 trial (COVID-OUT) provides virologic evidence explaining why metformin also reduces the risk of severe clinical outcomes and Long COVID, while other high-profile candidates like ivermectin and fluvoxamine showed no such effect.

What Problem Does This Paper Address?

While several antivirals exist for SARS-CoV-2, they face significant hurdles: high cost, limited global availability, and complex drug-drug interactions (notably with Paxlovid). Furthermore, most current treatments target specific viral proteins, which can lead to drug resistance as the virus mutates.

The researchers sought to validate a "host-targeted" approach. Instead of attacking the virus directly, they investigated whether a safe, existing drug could disrupt the host cellular machinery the virus hijacks to replicate. Specifically, biophysical modeling suggested that SARS-CoV-2 is highly dependent on the host's protein translation pathways. Metformin was identified as a candidate because it inhibits the mTOR pathway, a master regulator of protein synthesis.

Methods

The study was part of the COVID-OUT trial, a multi-site, decentralized, quadruple-blinded, randomized controlled trial.

  • Factorial Design: The trial used a 2x3 factorial design to simultaneously test three oral generic medications: metformin, ivermectin, and fluvoxamine.
  • Dosing: Metformin was titrated up to 1,500 mg daily over six days.
  • Virologic Monitoring: Participants self-collected nasal swabs on Days 1, 5, and 10.
  • Analysis: Viral load was measured via RT-qPCR. To handle samples where the virus was present but below the "limit of quantification," the authors used a linear Tobit regression model. This is a rigorous statistical approach for "left-censored" data that prevents bias when many participants have undetectable viral levels.
  • Adjustments: The analysis accounted for baseline viral load, vaccination status, the specific variant (Alpha, Delta, Omicron), and the timing of sample collection.

Datasets

The study analyzed data from the COVID-OUT trial cohort:

  • Total Randomized: 1,323 participants.
  • Sub-study Participants: 999 (76%) chose to provide nasal swabs.
  • Demographics: Adults aged 30–85 with a BMI in the overweight or obese category, all within three days of a positive test and seven days of symptom onset.
  • Benchmarks: The study compared metformin's performance against both a placebo and two other repurposed drugs (ivermectin and fluvoxamine).

Key Insights and Ideas

  • Host-Targeting Works: The study confirms that targeting host factors (like mTOR) is a viable strategy for reducing viral replication. This is a "future-proof" strategy because host pathways do not mutate as rapidly as viral proteins.
  • Dose-Response Correlation: The antiviral effect was stronger at Day 10 (-0.64 log₁₀ copies/mL) than at Day 5 (-0.47 log₁₀). This suggests the effect is dose-dependent, as participants reached their full 1,500 mg dose on Day 6.
  • Viral Rebound: Metformin reduced the incidence of "viral rebound" (where viral load increases again after an initial drop). Only 3.28% of the metformin group experienced rebound compared to 5.95% in the placebo group.
  • Consistency Across Variants: The drug's efficacy remained consistent across the Alpha, Delta, and Omicron waves, reinforcing the idea that host-targeted therapies are variant-agnostic.

Key Results

  • Viral Load Reduction: Metformin led to a mean reduction of -0.56 log₁₀ copies/mL across the study period compared to placebo. This translates to a 3.6-fold reduction in the amount of virus present.
  • Clinical Correlation: These virologic results mirror the trial's clinical findings, which showed a 42% reduction in ER visits/hospitalizations and a 42% reduction in Long COVID.
  • The "Failures": Neither ivermectin nor fluvoxamine showed any significant virologic effect compared to the placebo, effectively debunking their utility as antivirals in this clinical context.
  • Undetectable Levels: Participants in the metformin group were significantly more likely to reach undetectable viral levels by Day 10 (Odds Ratio 0.65).

Limitations and Future Work

  • Sampling Frequency: Swabs were only collected on Days 1, 5, and 10. More frequent sampling (e.g., daily) might have provided a more granular look at the kinetics of viral clearance.
  • Transmission: While the study proves metformin reduces the "viral load" in the individual, it does not directly measure whether this reduction is enough to decrease transmission to others.
  • Combination Therapy: The authors suggest that because metformin targets the host, it might have synergistic effects if used alongside direct-acting antivirals like Paxlovid or Molnupiravir. Future trials could explore these "cocktail" approaches.
  • Extended Release: This trial used immediate-release metformin. It remains unknown if extended-release formulations, which have different peak serum concentrations, would yield the same antiviral results.

Summary updated

Abstract

Abstract Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot be used with many medications, and are limited to virus-specific targets. 1-3 Biophysical modeling of SARS-CoV-2 replication predicted that protein translation is an especially attractive target for antiviral therapy. 4 Literature review identified metformin, widely known as a treatment for diabetes, as a potential suppressor of protein translation via targeting of the host mTor pathway. 5 In vitro, metformin has antiviral activity against RNA viruses including SARS-CoV-2. 6,7 In the COVID-OUT phase 3, randomized, placebo-controlled trial of outpatient treatment of COVID-19, metformin had a 42% reduction in ER visits/hospitalizations/death through 14 days; a 58% reduction in hospitalizations/death through 28 days, and a 42% reduction in Long COVID through 10 months. 8,9 Here we show viral load analysis of specimens collected in the COVID-OUT trial that the mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (−0.56 log 10 copies/mL; 95%CI, -1.05 to -0.06, p=0.027) while there was no virologic effect for ivermectin or fluvoxamine vs placebo. The metformin effect was consistent across subgroups and with emerging data. 10,11 Our results demonstrate, consistent with model predictions, that a safe, widely available, 12 well-tolerated, and inexpensive oral medication, metformin, can be repurposed to significantly reduce SARS-CoV-2 viral load.
BibTeX
@misc{bramante2023metformin,
  author = {Carolyn T. Bramante and Kenneth B. Beckman and Tanvi Mehta and Amy B. Karger and David J. Odde and Christopher J. Tignanelli and John B. Buse and Darrell M. Johnson and Ray Watson and Jerry J Daniel and David Liebovitz and Jacinda M. Nicklas and Ken Cohen and Michael A. Puskarich and Hrishikesh Belani and Lianne Siegel and Nichole R. Klatt and Blake Anderson and Katrina M Hartman and Via Rao and Aubrey A Hagen and Barkha Patel and Sarah L. Fenno and Nandini Avula and Neha V Reddy and Spencer M Erickson and Regina Fricton and Samuel Lee and Gwendolyn Griffiths and Matthew F Pullen and J. L. Thompson and Nancy E. Sherwood and Thomas A. Murray and Michael R. Rose and David R. Boulware and Jared D. Huling and the COVID-OUT study team},
  title = {{Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial}},
  year = {2023},
  doi = {10.1101/2023.06.06.23290989},
  howpublished = {medRxiv},
}
Figure